The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rosetta Genomics's Revenue for the
six
months ended in Jun. 2017 was $1.61 Mil. Rosetta Genomics's average Accounts Receivable for the
six
months ended in Jun. 2017 was $1.66 Mil.
Hence, Rosetta Genomics's Receivables Turnover for the
six
months ended in Jun. 2017 was 0.97.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Rosetta Genomics Receivables Turnover Related Terms
Rosetta Genomics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROSGQ vs TEAR, IDTA, ABMC: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Rosetta Genomics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics (ROSGQ) has a Receivables Turnover of 0.97 as of Jun. 2017. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Receivables Turnover too high?
Rosetta Genomics' current Receivables Turnover is 0.97. The Medical Diagnostics & Research industry median Receivables Turnover is 5.37. Rosetta Genomics' value of 0.97 is 81.9% below this industry median.
How does Rosetta Genomics' Receivables Turnover compare to TEAR and IDTA?
Rosetta Genomics' Receivables Turnover of 0.97 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Receivables Turnover is 5.37. Rosetta Genomics' value of 0.97 is 81.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.37, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Receivables Turnover of 0.97 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Receivables Turnover is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Receivables Turnover of 0.97. The current Receivables Turnover is 0.97 and 81.9% below the Medical Diagnostics & Research industry median of 5.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Receivables Turnover is 0.97 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 